Humoral immunity against SARS-CoV-2 variants including omicron in solid organ transplant recipients after three doses of a COVID-19 mRNA vaccine.
Author
Saharia, Kapil KHusson, Jennifer S
Niederhaus, Silke V
Iraguha, Thierry
Avila, Stephanie V
Yoo, Youngchae J
Hardy, Nancy M
Fan, Xiaoxuan
Omili, Destiny
Crane, Alice
Carrier, Amber
Xie, Wen Y
Vander Mause, Erica
Hankey, Kim
Bauman, Sherri
Lesho, Patricia
Mannuel, Heather D
Ahuja, Ashish
Mathew, Minu
Avruch, James
Baddley, John
Goloubeva, Olga
Shetty, Kirti
Dahiya, Saurabh
Rapoport, Aaron P
Luetkens, Tim
Atanackovic, Djordje
Date
2022-04-29Journal
Clinical & Translational ImmunologyPublisher
Wiley-BlackwellType
Article
Metadata
Show full item recordAbstract
Following the initial vaccination series, 60.3% of SOTR showed no measurable neutralisation and only 18.9% demonstrated neutralising activity of > 90%. More intensive immunosuppression, antimetabolites in particular, negatively impacted antiviral immunity. While absolute IgG levels were lower in SOTR than controls, antibody titres against microbial recall antigens were higher. By contrast, SOTR showed reduced vaccine-induced IgG/IgA antibody titres against SARS-CoV-2 and its delta variants and fewer linear B-cell epitopes, indicating reduced B-cell diversity. Importantly, a third vaccine dose led to an increase in anti-SARS-CoV-2 antibody titres and neutralising activity across alpha, beta and delta variants and to the induction of anti-SARS-CoV-2 CD4+ T cells in a subgroup of patients analysed. By contrast, we observed significantly lower antibody titres after the third dose with the omicron variant compared to the ancestral SARS-CoV-2 and the improvement in neutralising activity was much less pronounced than for all the other variants.Rights/Terms
© 2022 The Authors. Clinical & Translational Immunology published by John Wiley & Sons Australia, Ltd on behalf of Australian and New Zealand Society for Immunology, Inc.Identifier to cite or link to this item
http://hdl.handle.net/10713/18773ae974a485f413a2113503eed53cd6c53
10.1002/cti2.1391
Scopus Count
Related articles
- Neutralizing antibody response against the B.1.617.2 (delta) and the B.1.1.529 (omicron) variants after a third mRNA SARS-CoV-2 vaccine dose in kidney transplant recipients.
- Authors: Benning L, Morath C, Bartenschlager M, Kim H, Reineke M, Beimler J, Buylaert M, Nusshag C, Kälble F, Reichel P, Töllner M, Schaier M, Klein K, Benes V, Rausch T, Rieger S, Stich M, Tönshoff B, Weidner N, Schnitzler P, Zeier M, Süsal C, Hien Tran T, Bartenschlager R, Speer C
- Issue date: 2022 Jul
- Humoral immune response after different SARS-CoV-2 vaccination regimens.
- Authors: Rose R, Neumann F, Grobe O, Lorentz T, Fickenscher H, Krumbholz A
- Issue date: 2022 Jan 21
- Neutralising reactivity against SARS-CoV-2 Delta and Omicron variants by vaccination and infection history.
- Authors: Lavezzo E, Pacenti M, Manuto L, Boldrin C, Cattai M, Grazioli M, Bianca F, Sartori M, Caldart F, Castelli G, Nicoletti M, Nieddu E, Salvadoretti E, Labella B, Fava L, Vanuzzo MC, Lisi V, Antonello M, Grimaldi CI, Zulian C, Del Vecchio C, Plebani M, Padoan A, Cirillo DM, Brazzale AR, Tonon G, Toppo S, Dorigatti I, Crisanti A
- Issue date: 2022 Jun 10
- Previous SARS-CoV-2 infection or a third dose of vaccine elicited cross-variant neutralising antibodies in vaccinated solid-organ transplant recipients.
- Authors: Chang CC, Vlad G, Vasilescu ER, Li P, Husain SA, Silvia EA, Cohen DJ, Ratner LE, Sun WZ, Mohan S, Suciu-Foca N
- Issue date: 2022
- SARS-CoV-2-specific antibody and T-cell responses 1 year after infection in people recovered from COVID-19: a longitudinal cohort study.
- Authors: Guo L, Wang G, Wang Y, Zhang Q, Ren L, Gu X, Huang T, Zhong J, Wang Y, Wang X, Huang L, Xu L, Wang C, Chen L, Xiao X, Peng Y, Knight JC, Dong T, Cao B, Wang J
- Issue date: 2022 May